Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer

Immunotherapy for advanced melanoma: Fulfilling the promise

(2013) Helen Gogas et al.   CANCER TREATMENT REVIEWS

Primary 4T1 tumor resection provides critical “window of opportunity” for immunotherapy

(2013) Anahit Ghochikyan et al.   CLINICAL & EXPERIMENTAL METASTASIS

Combined Stimulation of Toll-Like Receptor 5 and NOD1 Strongly Potentiates Activity of NF-κB, Resulting in Enhanced Innate Immune Reactions and Resistance to Salmonella enterica Serovar Typhimurium Infection

(2013) Amir I. Tukhvatulin et al.   INFECTION AND IMMUNITY

Links between Toll-like receptor 4 and breast cancer

(2013) Abubakr Ahmed et al.   OncoImmunology

Silencing of TLR4 Increases Tumor Progression and Lung Metastasis in a Murine Model of Breast Cancer

(2012) Abubakr Ahmed et al.   ANNALS OF SURGICAL ONCOLOGY

Primary systemic therapy in HER2-amplified breast cancer: a clinical review

(2012) Mustafa Khasraw et al.   Expert Review of Anticancer Therapy

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical trial results of the HER-2/neu(E75) vaccine to prevent breast cancer recurrence in high-risk patients

(2011) Elizabeth A. Mittendorf et al.   CANCER

Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma

(2011) Mikayel Mkrtichyan et al.   CELLULAR IMMUNOLOGY

Tumor- and organ-dependent infiltration by myeloid-derived suppressor cells

(2011) Ibrahim Younos et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy

(2010) Gerty Schreibelt et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

TAK-242 (Resatorvid), a Small-Molecule Inhibitor of Toll-Like Receptor (TLR) 4 Signaling, Binds Selectively to TLR4 and Interferes with Interactions between TLR4 and Its Adaptor Molecules

(2010) N. Matsunaga et al.   MOLECULAR PHARMACOLOGY

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies

(2010) Paolo A. Ascierto et al.   SEMINARS IN ONCOLOGY

Immunomax®therapy to obtain relief in papilloma virus infections, prostatitis, and prostate carcinoma

(2010) Ravshan Ataullakhanov et al.   Journal of Mens Health

TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain

(2008) Tomohiro Kawamoto et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Twelve immunotherapy drugs that could cure cancers

(2008) Martin A. ‘Mac’ Cheever   IMMUNOLOGICAL REVIEWS